Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL16569145 | 0.92 | S1PR1 (0.32) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| Glycine SCHEMBL16569115 | 0.92 | GLRA1 (0.40) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL6130102 | 0.87 | ALOX15 (0.32) | MEN1KMT2A | |
| SCHEMBL25302909 | 0.81 | — | — | |
| SCHEMBL221073 | 0.80 | PTPN1 (0.40) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL10831561 | 0.78 | MEN1 (0.31) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL456197 | 0.76 | MEN1 (0.48) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL1500317 | 0.76 | MEN1 (0.30) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL2102896 | 0.76 | MEN1 (0.30) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL2958109 | 0.76 | PTPN1 (0.32) | MEN1ALDH1A1CYP1A2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752253-B | Multi-nitrogen heterocyclic non-natural chiral amino acid and synthesis method thereof | 深圳市茵诺圣生物科技有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-108752253-B | Multi-nitrogen heterocyclic non-natural chiral amino acid and synthesis method thereof | 深圳市茵诺圣生物科技有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-2797900-B1 | COMPLEX-FORMING COMPOUNDS | STRATOXER S KFT (HU) | 2016-09-28 | — | — | EP | disclosed |
| US-20160220689-A1 | MACROMOLECULES OF DENDRIMER-PLATINUM CONJUGATES | STARPHARMA PTY LTD. (AU) | 2016-08-04 | — | — | US | disclosed |
| US-9243031-B2 | Complex-forming compounds | STRATOXER(S) KFT. (HU) | 2016-01-26 | — | — | US | disclosed |
| WO-2015035446-A1 | MACROMOLECULES OF DENDRIMER-PLATINUM CONJUGATES | STARPHARMA PTY LTD (AU) | 2015-03-19 | — | — | WO | disclosed |
| US-20140342997-A1 | COMPLEX-FORMING COMPOUNDS | STRATOXER(S) KFT. (HU) | 2014-11-20 | — | — | US | disclosed |
| EP-2797900-A1 | COMPLEX-FORMING COMPOUNDS | Stratoxer(S) Kft. (HU) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013098572-A1 | COMPLEX-FORMING COMPOUNDS | STRATOXER(S) KFT. (HU) | 2013-07-04 | — | — | WO | disclosed |
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | ALPP, PPIP5K2, ALPI | MEN1 2130/4885ALDH1A1 633/4885CYP1A2 1658/4885 |
| US-20160220689-A1 | MACROMOLECULES OF DENDRIMER-PLATINUM CONJUGATES | CD44, FOLR1, FOLH1 | MEN1 1146/4885ALDH1A1 610/4885CYP1A2 2713/4885 |
| US-20140342997-A1 | COMPLEX-FORMING COMPOUNDS | F2, CYP2F1, CYP4F2 | MEN1 95/4885ALDH1A1 1706/4885CYP1A2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.